• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Third party research

Generic: Ends 2024 in style - ABG

Generic Sweden

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
24% organic sales growth y-o-y
Improved gross margin due to pricing and mix
Opex flat y-o-y leads to 48% EBIT growth


Q4: Sales growth of 24%, EBIT margin of 22.7% (19.0%)

Generic continued its impressive comeback in Q4, where H1'24 profitability issues appear to have been overcome in H2'24. Sales growth in Q4 remained strong at 24% y-o-y (all organic), the gross margin improved 230bp q-o-q to 43.8% due to pricing and a higher proportion of SaaS revenues, and opex was flat y-o-y. This resulted in sales of SEK 48m (SEK 39m) and EBIT of SEK 10.9m (SEK 7.3m), which was in line with ABGSCe on sales but 23% better on EBIT. The majority of the deviation was driven by higher gross margin and the rest was from lower opex than we expected. Cash flow improved 12% y-o-y and the board proposed an improved dividend of SEK 1.60 (1.50)